Blockchain Registration Transaction Record

Tenpoint Therapeutics Names Melissa Epperly CFO Ahead of Key Drug Launch

Tenpoint Therapeutics appoints Melissa Epperly as CFO, signaling a strategic move towards the U.S. launch of BRIMOCHOL PF for presbyopia treatment.

The appointment of Melissa Epperly as CFO of Tenpoint Therapeutics marks a pivotal moment for the company as it gears up for the potential U.S. launch of BRIMOCHOL PF, a groundbreaking treatment for presbyopia. With her proven track record in financial leadership and capital markets, Epperly is poised to drive Tenpoint's transition into a commercial-stage entity, bringing innovative treatments to millions suffering from vision impairments. This development is significant for investors, patients, and the broader biotech industry, highlighting the potential for transformative therapies in addressing age-related eye conditions.